興科蓉醫藥(06833.HK):年度業績扭虧為盈約2200萬元至3200萬元
格隆匯3月5日丨興科蓉醫藥(06833.HK)發佈公告,預期集團於截至2019年12月31日止年度將錄得綜合純利約人民幣2200萬元至3200萬元(須待落實該期間的經審核綜合財務業績後,方可作實),而對比上年同期的綜合虧損淨額則約為人民幣2.806億元。
公告表示,集團純利於該期間轉虧為盈的主要因素包括(其中包括)有監於中國醫藥行業於2017及2018年執行“兩票制”,集團已完成了對銷售渠道及營銷網絡的重建及重新開發,因此,與2019年上半年度的情況一致,集團於該期間的銷售及經銷開支較同期整體減少;及鑑於集團已償還很大部份於同期存在的計息銀行借款,故該期間的財務成本較同期減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.